CGM Can Improve Diabetes Control. Heart Benefits Remain Unsettled

Continuous glucose monitoring (CGM) improves blood sugar control in type 2 diabetes, including for people who do not use insulin. The more provocative claim—that CGM also lowers blood pressure, triglycerides, cholesterol, and body weight—has support from a new meta-analysis, but a recent high-quality review found none of those benefits. The glucose result is established. The cardiovascular-risk story is not.

That distinction matters for anyone paying out of pocket to wear a sensor. CGM can turn meals, exercise, sleep, and medication into visible glucose data. It cannot yet promise that those data will prevent heart disease, especially in people without diabetes.

What the largest recent review found

A 2026 meta-analysis of 30 randomized controlled trials, including 3,133 people with type 2 diabetes, found that patient-accessible CGM lowered HbA1c by an average of 0.48 percentage points versus the comparator conditions. HbA1c estimates average blood glucose over roughly two to three months, so this is a useful clinical measure, not merely a prettier graph on an app.

Device type mattered. Real-time CGM, which continuously displays readings and can provide alerts, was associated with a 0.65-percentage-point HbA1c reduction. Intermittently scanned CGM, often called flash CGM, was associated with a 0.25-point reduction. The review also reported a 10.76-percentage-point increase in time in range.

Its secondary-outcome results drew more attention: systolic blood pressure fell by 3.47 mmHg, triglycerides by 32.17 mg/dL, non-HDL cholesterol by 9.31 mg/dL, body weight by 3.26 kg, and BMI by 0.87 kg/m². All were reported as statistically significant at p<0.001.

Those numbers are encouraging, but they do not prove that a sensor itself changed cardiovascular risk. Most trials were designed around glycemic outcomes, not blood pressure, lipids, or clinical events such as heart attack. A pooled result from secondary endpoints can generate a credible hypothesis; it cannot settle it.

The evidence is strongest for glycemic control

Several independent reviews point in the same direction on glucose control in type 2 diabetes. A 2023 Diabetes Care meta-analysis of 26 randomized trials and 2,783 participants found that CGM and intermittently scanned CGM improved HbA1c versus standard care. A 2024 Diabetologia review independently reached the same broad glycemic conclusion.

The evidence also applies to people with type 2 diabetes who are not taking insulin, although the dedicated trial base remains small. A 2024 meta-analysis of six randomized trials included 407 non-insulin-treated participants, 228 assigned to CGM. CGM lowered HbA1c by 0.31 percentage points (95% CI, −0.42 to −0.21), raised time in range by 8.63 percentage points (95% CI, 4.54 to 12.71), and lowered mean glucose by 11.16 mg/dL (95% CI, −19.94 to −2.39).

For HbA1c and time in range, statistical heterogeneity was zero (I²=0%), meaning these six trials produced unusually consistent estimates. Consistency helps. It does not transform 407 participants into a large long-term outcomes program. The trials involved adults with established type 2 diabetes: mean age was 57.9 years, mean BMI was 30.8 kg/m², and diabetes duration ranged from 5.4 to 13.9 years across trials.

Two trials illustrate the practical use case. The IMMEDIATE randomized trial tested flash monitoring in people with type 2 diabetes inadequately controlled on non-insulin antihyperglycemic therapy. A later Dexcom G6 randomized trial enrolled non-insulin-treated participants at elevated cardiovascular risk and assessed glycemic control and cardiometabolic endpoints. These are clinical diabetes populations, not healthy people trying to optimize a breakfast smoothie.

Why the cardiometabolic claim remains unsettled

The 2026 review and the 2023 Diabetes Care review disagree directly. The older review found no significant effects on blood pressure, lipids, body composition, or weight. The newer review found statistically significant improvements across those measures.

The reviews did not search the same literature. The 2023 review searched through August 2023, while the 2026 review searched through April 2025 and included four additional randomized trials. The 2024 trial in people at high cardiovascular risk is a plausible contributor to the newer positive estimates because it appeared after the earlier review's cutoff and explicitly included cardiometabolic endpoints. That is an inference, however; without participant-level analyses showing which studies drove each pooled result, the reason for the shift remains uncertain.

Neither result should be waved away. Both are peer-reviewed meta-analyses of randomized trials. But neither body of evidence was built primarily to test whether CGM lowers cardiovascular risk. Blood pressure, lipids, and weight were secondary endpoints in virtually all of the included trials. Treat the new findings as a signal worth testing in purpose-built trials, not as proof that a sensor substitutes for established cardiovascular care.

There is a broader methodological reason for restraint. A 2025 systematic review of real-time CGM trials in type 2 diabetes reviewed 11 randomized trials but declined to pool them because interventions, participants, and outcomes differed too much. Across the literature, follow-up ranged from 12 weeks to 12 months in the dedicated non-insulin review. Devices, baseline HbA1c, comparators, and the support given alongside CGM also vary. A single pooled number can be useful, but it is not a universal prescription.

Feedback appears to be part of the treatment

CGM does not lower glucose by sitting quietly on an arm. Its likely value comes from feedback: people and clinicians can change food, activity, and treatment in response to the readings. In a randomized study of 273 adults with type 1 diabetes, unblinded intermittently scanned CGM improved time in range at 12 weeks, whereas blinded monitoring did not show that increase. Participants wearing the blinded device could not see the sensor data themselves.

For device choice, a 2024 meta-analysis in adults with type 1 diabetes found that real-time CGM produced better glycemic control than flash monitoring. It compared CGM modalities with each other, not with finger-stick monitoring. The type 2 diabetes review's larger HbA1c reduction with real-time versus intermittently scanned CGM points in the same direction, though the populations differ.

CGM has costs beyond its price tag

More data does not automatically produce a better experience. The 2023 Diabetes Care review found lower user satisfaction with CGM than with standard blood glucose monitoring, with a weighted mean difference of −0.54 (95% CI, −0.98 to −0.11). It also found more adverse events with CGM: relative risk 1.22 (95% CI, 1.01 to 1.47). The confidence interval barely excludes no difference, so this is a modest signal, not a major safety alarm. Sensor-site skin reactions and the everyday burden of alarms and device wear remain real tradeoffs.

What this means for healthy CGM users

For non-insulin-treated type 2 diabetes, randomized evidence supports CGM as a tool to improve HbA1c and time in range. The magnitude is modest but measurable, and the results across the six dedicated trials were consistent. A person considering CGM should use the data to support concrete changes with a clinician or diabetes educator, rather than treating each post-meal rise as a personal failing.

For people without diabetes, the outcome evidence has not arrived. A 2024 systematic review in people without diabetes found associations between CGM-measured glucose variability and cardiometabolic risk markers. Associations can identify a pattern; they cannot show that wearing a CGM improves health or that glucose variability causes the observed risk markers.

CGM is well supported for improving glycemic measures in type 2 diabetes. Its reported effects on blood pressure and lipids need confirmation, and healthy users should view the device as a learning tool rather than a proven longevity intervention.

A sensor can reveal patterns worth discussing and can make behavior easier to test. It has not yet earned a promise of cardiometabolic benefit for metabolically healthy adults.